Mundt et al. found that CHEK2 truncating variants confer 1.8-fold increased risk of DCIS, and CHEK2 c.470T > C missense variant increases the risk by 1.3-fold (p = 0.02) [51]. This evidence concerns the gene CHEK2 and ductal breast carcinoma in situ.